Product Description
Mechanisms of Action: CCK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Trio Medicines
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Carcinoid Tumor|Gastritis, Atrophic|Gastritis|Barrett Esophagus|Healthy Volunteers|Zollinger-Ellison Syndrome|Gastrinoma
Phase 1: Healthy Volunteers|Esophagitis, Peptic|Dyspepsia|Pregnancy Outcomes|Peptic Ulcer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02620696 |
T-013 | P1 |
Completed |
Dyspepsia |
2010-09-01 |
2019-03-20 |
Treatments |
|
NCT01699113 |
NCT01699113 | P1 |
Completed |
Pregnancy Outcomes|Peptic Ulcer|Dyspepsia |
2007-06-01 |
2019-03-19 |
Treatments |
|
NCT01601418 |
NCT01601418 | P1 |
Completed |
Healthy Volunteers |
2002-01-01 |
2019-03-19 |
Treatments |
|
NCT01601405 |
NCT01601405 | P1 |
Completed |
Healthy Volunteers |
2001-11-01 |
2019-03-19 |
Treatments |
|
NCT01597674 |
NCT01597674 | P1 |
Completed |
Esophagitis, Peptic |
1997-06-01 |
2019-03-19 |
Treatments |
|
NCT01599858 |
YF476 | P1 |
Completed |
Esophagitis, Peptic |
1996-10-01 |
2019-03-19 |
Treatments |
|
NCT01538797 |
YF476 | P1 |
Completed |
Esophagitis, Peptic |
1996-08-01 |
2019-03-19 |
Treatments |
|
NCT01538784 |
NCT01538784 | P1 |
Completed |
Esophagitis, Peptic |
1996-06-01 |
2019-03-19 |
Treatments |
|
2007-002916-24 |
YF476 and type I gastric carcinoids | P2 |
Completed |
Gastritis, Atrophic |
2020-01-27 |
2022-03-12 |
Treatments |
|
2014-002418-22 |
Netazepide (YF476) in patients with Barrett's oesophagus; version 1 | P2 |
Completed |
Barrett Esophagus |
2019-10-10 |
2022-03-13 |
Treatments |
|
NCT01298999 |
AAAE9648 | P2 |
Completed |
Barrett Esophagus |
2017-12-01 |
12% |
2021-11-24 |
Patient Enrollment|Primary Endpoints|Treatments |
NCT02597712 |
T-016 | P2 |
Completed |
Barrett Esophagus |
2017-11-28 |
2021-04-13 |
||
2012-002183-27 |
Gastroscopy study of netazepide and H. pylori infection; version 1 | P2 |
Unknown status |
Gastritis |
2014-12-24 |
2022-03-13 |
Treatments |
|
NCT01339169 |
T-008 | P2 |
Completed |
Gastritis, Atrophic|Carcinoid Tumor |
2013-12-10 |
2019-08-21 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
2007-002137-37 |
YF476 and H. pylori | P2 |
Completed |
Healthy Volunteers |
2012-07-18 |
2022-03-12 |
Treatments |
|
NCT02454075 |
T-010 | P2 |
Terminated |
Gastrinoma|Carcinoid Tumor|Zollinger-Ellison Syndrome |
2012-06-22 |
2021-01-29 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
|
NCT01444014 |
Norway | P2 |
Terminated |
Gastritis, Atrophic|Carcinoid Tumor |
2012-05-01 |
2019-03-19 |
Treatments |